avelumab
E822413
Avelumab is a human monoclonal antibody immunotherapy drug used to treat certain cancers by blocking the PD-L1 immune checkpoint pathway.
Statements (48)
| Predicate | Object |
|---|---|
| instanceOf |
antineoplastic agent
ⓘ
immunotherapy drug ⓘ monoclonal antibody ⓘ |
| administrationSetting | healthcare facility ⓘ |
| antibodyType | IgG1 ⓘ |
| belongsTo | checkpoint inhibitor therapies ⓘ |
| bindsTo | programmed death-ligand 1 NERFINISHED ⓘ |
| combinationIndication | first-line treatment of advanced renal cell carcinoma with axitinib ⓘ |
| commonAdverseEffect |
diarrhea
ⓘ
fatigue ⓘ infusion-related reactions ⓘ nausea ⓘ rash ⓘ |
| contraindicationCaution | severe immune-mediated toxicity history ⓘ |
| developedBy |
Merck KGaA
NERFINISHED
ⓘ
Pfizer NERFINISHED ⓘ |
| dosingSchedule | every 2 weeks in many indications ⓘ |
| firstFDAApprovalYear | 2017 ⓘ |
| hasATCCode | L01FF03 ⓘ |
| hasGenericName | avelumab NERFINISHED ⓘ |
| hasHalfLifeApprox | 6 days to 7 days ⓘ |
| hasTradeName | Bavencio NERFINISHED ⓘ |
| immuneRelatedAdverseEffect |
colitis
ⓘ
endocrinopathies ⓘ hepatitis ⓘ pneumonitis ⓘ |
| indicationRegion |
European Union
NERFINISHED
ⓘ
United States NERFINISHED ⓘ |
| indicationType | oncology ⓘ |
| isFullyHuman | true ⓘ |
| isHuman | true ⓘ |
| isPrescriptionOnly | true ⓘ |
| isRecombinant | true ⓘ |
| mechanismOfAction |
blocks PD-1/PD-L1 interaction
ⓘ
enhances T-cell mediated immune response against tumor cells ⓘ |
| pharmacologicClass | PD-L1 blocking antibody ⓘ |
| regulatoryApproval |
EMA-approved
ⓘ
FDA-approved ⓘ |
| requiresMonitoringFor | immune-mediated adverse reactions ⓘ |
| routeOfAdministration | intravenous infusion ⓘ |
| targets | PD-L1 NERFINISHED ⓘ |
| treats |
locally advanced Merkel cell carcinoma
ⓘ
locally advanced renal cell carcinoma ⓘ locally advanced urothelial carcinoma ⓘ metastatic Merkel cell carcinoma ⓘ metastatic renal cell carcinoma ⓘ metastatic urothelial carcinoma ⓘ |
| usedInCombinationWith | axitinib ⓘ |
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.